KR100769299B1 - Lactobacillus fermentum and dairy products and health-promoting food containing the same - Google Patents
Lactobacillus fermentum and dairy products and health-promoting food containing the same Download PDFInfo
- Publication number
- KR100769299B1 KR100769299B1 KR1020040104153A KR20040104153A KR100769299B1 KR 100769299 B1 KR100769299 B1 KR 100769299B1 KR 1020040104153 A KR1020040104153 A KR 1020040104153A KR 20040104153 A KR20040104153 A KR 20040104153A KR 100769299 B1 KR100769299 B1 KR 100769299B1
- Authority
- KR
- South Korea
- Prior art keywords
- alcohol
- lactobacillus
- lactic acid
- acid bacteria
- liver
- Prior art date
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 12
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 11
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 95
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 64
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 32
- 239000004310 lactic acid Substances 0.000 claims abstract description 32
- 230000036541 health Effects 0.000 claims abstract description 9
- 235000013373 food additive Nutrition 0.000 claims abstract description 8
- 239000002778 food additive Substances 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 24
- 108090000790 Enzymes Proteins 0.000 abstract description 24
- 230000000593 degrading effect Effects 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 12
- 208000022309 Alcoholic Liver disease Diseases 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 5
- 235000018291 probiotics Nutrition 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 206010019133 Hangover Diseases 0.000 abstract description 3
- 238000001784 detoxification Methods 0.000 abstract description 3
- 230000035622 drinking Effects 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 77
- 241000186660 Lactobacillus Species 0.000 description 46
- 229940039696 lactobacillus Drugs 0.000 description 45
- 229940035901 lactobacillus sp Drugs 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 22
- 239000002609 medium Substances 0.000 description 16
- 150000001299 aldehydes Chemical class 0.000 description 9
- 210000000805 cytoplasm Anatomy 0.000 description 9
- 210000003494 hepatocyte Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 239000002932 luster Substances 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 3
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 3
- 240000001929 Lactobacillus brevis Species 0.000 description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 208000002353 alcoholic hepatitis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000245772 Gasteria Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000005415 magnetization Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/143—Fermentum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 알코올 분해능이 있는 유산균 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제에 관한 것으로서, 보다 상세하게는 알코올 내성과 분해능이 우수한 유산균을 선발하고, 상기 유산균을 첨가하여 음주 후 알코올 분해에 따른 숙취해소 효과와 간의 해독작용을 도와 향후 알코올성 간 질환을 예방할 수 있는 식품 등의 제조에 광범위하게 활용될 수 있는 알코올 분해능이 있는 유산균 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제에 관한 것이다.The present invention relates to lactic acid bacteria having alcohol degrading ability and dairy products, health functional foods and food additives containing the same, and more particularly, to select lactic acid bacteria having excellent alcohol resistance and degradability, and adding the lactic acid bacteria to alcohol after drinking The present invention relates to a lactic acid bacterium having an alcohol degradable property and a dairy product, a health functional food, and a food additive containing the same, which can be widely used in the manufacture of foods such as a hangover-relieving effect and liver detoxification, which can prevent alcoholic liver disease.
락토바실러스 퍼멘텀, 프로바이오틱스, 알코올성 간 질환, 알코올 분해효소, 알데하이드 분해효소Lactobacillus fermentum, probiotics, alcoholic liver disease, alcohol degrading enzyme, aldehyde degrading enzyme
Description
도 1은 SDS-PAGE를 통하여 효소 확인한 사진.1 is a photograph confirming the enzyme through the SDS-PAGE.
도 2는 간세포 배양을 통해 간 기능 효과를 검사한 사진.Figure 2 is a photograph examining the effect of liver function through hepatocyte culture.
본 발명은 알코올 분해능이 우수한 락토바실러스(Lactobacillus)속의 새로운 유산균인 락토바실러스 퍼멘텀 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제에 관한 것으로서, 보다 상세하게는 알코올 내성과 분해능이 우수한 유산균을 선발함으로써, 상기 유산균을 첨가하여 음주 후 알코올 분해에 따른 숙취해소 효과와 간의 해독작용을 도와 향후 알코올성 간 질환을 예방할 수 있는 식품 등의 제조에 광범위하게 활용될 수 있는 알코올 분해능이 있는 유산균 및 그를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제에 관한 것이다.The present invention relates to a new lactic acid bacterium Lactobacillus (Lactobacillus) having excellent alcohol resolution, and dairy products, health functional foods and food additives containing the same, and more particularly, by selecting lactic acid bacteria having excellent alcohol resistance and resolution. , Lactic acid bacteria by adding lactic acid bacteria to help the hangover and the detoxification effect of alcohol after drinking alcohol to prevent alcoholic liver disease in the future can be widely used in the production of foods such as alcohol lactic acid bacteria and dairy products containing them , Health functional foods and food additives.
간은 우리 몸에서 에너지 대사를 전체적으로 관리하며 빌리루빈, 담즙산, 콜레스테롤, 인지질 등의 각종 대사산물 및 합성물을 저장하거나 온몸에 분배하는 기 능을 갖고, 독소를 해독하거나 주요한 면역기관으로서의 역할을 담당하는 매우 중요한 기관이다.The liver manages energy metabolism in our body as a whole and has the ability to store or distribute various metabolites and compounds such as bilirubin, bile acids, cholesterol, and phospholipids throughout the body, detoxifying toxins or serving as a major immune organ. It is an important organ.
현재 국내에서 질병에 의한 사망원인을 보면, 간질환에 의해 사망하는 순위가 인구 10만명당 22.9명(2001년 기준)으로 4위에 올라와 있으며, 이중 알코올 섭취에 의한 간 질환자를 무시할 수 없다. 세계 보건기구가 96년 153개 국가를 대상으로 음주량을 조사한 결과, 우리나라 성인 1인당 알코올 섭취량은 연간 14,4ℓ로 세계 2위로 나타났으며, 해마다 음주로 인한 사고와 질병으로 2만 3천여명이 숨지며, 이로 인한 경제적 손실도 16조원에 달한다고 발표하였다. 또한, 우리나라 성인 중 알코올 중독자 비율이 21.6%로 세계 최고 수준이며, 성인 5명 중 1명은 알코올 중독자로 심한 국민병에 다다르고 있다.Currently, the cause of mortality caused by disease in the country, the rank of death from liver disease is ranked 4th with 22.9 people per 100,000 population (as of 2001), and the liver disease due to alcohol consumption can not be ignored. According to the World Health Organization's alcohol consumption survey in 153 countries in 1996, Korea's adult alcohol consumption per capita was 14,4ℓ per year, ranking 2nd in the world, and 23,000 people died of accidents and diseases caused by alcohol every year. It also announced that the economic loss amounted to 16 trillion won. In addition, the proportion of alcoholics among Korean adults is 21.6%, the highest in the world, and one out of five adults is suffering from severe national illness as an alcoholic.
알코올성 간질환은 지속적이고 과다한 음주에 의해서 유발되는 간세포 손상을 동반하는 급/만성 간질환으로, 간에는 알코올을 분해하는 효소들이 존재하여 알코올을 알데하이드를 거쳐 분해하는데, 상기 아세트알데하이드가 독성을 나타내어 간세포에 손상을 입히게 된다. Alcoholic liver disease is acute / chronic liver disease with hepatocellular damage caused by persistent and excessive drinking. In the liver, there are enzymes that break down alcohol and decompose alcohol through aldehydes. Acetaldehyde is toxic to liver cells. It will be damaged.
이러한 알코올성 간질환은 크게 알코올성 지방간, 알코올성 간염, 알코올성 간경변으로 분류되는데 간 손상 기전은 알코올 자체에 의한 경우, 아세트알데하이드와 같은 대사산물에 의한 경우, 면역반응에 의한 경우 등이 있으며, 특히 아세트알데하이드는 지방의 페록시데이션(Peroxidation), 세포질과의 결합, 미토콘드리아의 전자전달계 교란, 마이크로터블(Microtuble)의 기능방해, 단백질과 결합물질 형성, 콜라겐 합성의 증가 등 간 독성의 주범으로 작용한다.These alcoholic liver diseases are classified into alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis. The mechanism of liver damage may be due to alcohol itself, metabolites such as acetaldehyde, or immune response. Peroxidation of fat, binding to cytoplasm, disruption of electron transport systems in mitochondria, disruption of microtuble, formation of proteins and binding substances, increased collagen synthesis, etc.
알코올은 위에서 20% 정도가 흡수되고 나머지는 대부분 소장에서 흡수되어 이중 80~90%가 간에서 대사되므로 간에 의한 알코올 대사 중 많은 부분을 소장 및 대장에서 처리할 수 있다면 간의 부담을 덜 수 있고, 나아가 간 손상을 억제할 수 있을 것이다. Alcohol is absorbed by about 20% in the stomach and most of the rest is absorbed in the small intestine, 80-90% of the metabolism in the liver, so much of the liver's alcohol metabolism can be treated in the small and large intestine, less burden on the liver, further It may be able to suppress liver damage.
그러므로, 알코올은 체내에 저장되지 못하기 때문에 대사가 되어야 하는데, 이 과정은 대부분 간에서 이루어지며 이러한 대사는 간에 존재하는 알코올분해 효소들에 의해 이루어진다. 알코올은 이러한 효소들에 의해 아세트알데하이드란 물질을 거쳐 분해되는데, 상기 아세트알데하이드는 독성이 있어 간세포에 손상을 주게 된다. 그리고, 알코올 대사 결과 지방산이 많이 만들어져 간에 지방이 축적되는데 이를 알코올성 지방간이라고 한다. 상기 알코올성 지방간은 만성 간질환으로 진행되는 경우가 많은데, 알코올성 간염이 10~35%에서 간경변증이 8~20%에서 발생된다고 한다.Therefore, because alcohol is not stored in the body, it must be metabolized, which is mostly done in the liver, and this metabolism is done by alcohol-degrading enzymes present in the liver. Alcohol is broken down through acetaldehyde by these enzymes, which are toxic and damage liver cells. And, as a result of alcohol metabolism, many fatty acids are made and fat is accumulated in the liver, which is called alcoholic fatty liver. The alcoholic fatty liver is often progressed to chronic liver disease, alcoholic hepatitis is said to occur in 10 to 35% cirrhosis in 8 to 20%.
최근 장내 유익균으로 각광을 받고 있는 프로바이오틱스(Probiotics)는 질병의 예방 및 치료에 다양하게 적용되고 있으며, 특히 장내 부패균과 병원균에 대한 증식과 부패활동을 억제하는 효과가 있다고 널리 알려져 있다. (Schrezenmeir J, De Vrese M: Am J Clin Nutr. 73(2001), P 361S-4S) 프로바이오틱스는 암모니아나 아민 등을 생성하는 유해균의 증식을 억제하여 중독성 물질의 생성량을 억제시킴으로서 혈중 암모니아 및 알파 아미노 질소량이 감소하여 간 질환자의 증상을 개선시킨다는 보고도 발표되었다. 또한, 이러한 유용한 균들 중에 알코올로부터 간을 보호하고 간의 특이 기능을 향상시켜 준다는 결과가 보고되었다. (Raibaud, P: The 3rd International Synposium on Lactic Acid Bacteria and Human Health. (1983), P116-126) 최근에 프로바이오틱스 락토바실러스(Probiotics lactobacillus)와 비피도박테리움(Bifidobacterium)과 같은 유용한 유산균을 이용하여 알코올 대사를 활발하게 촉진시켜 알코올을 신속하게 분해하고 이러한 과정에서 생성되는 인체에 유해한 아세트알데하이드를 대사하여 무독화시키는 가능성의 연구 결과가 보고되었다. (Nosava. T. et al: Alcohol and Alcoholism. 35(2000), P561-568)Recently, probiotics, which have been spotlighted as enteric beneficial bacteria, have been widely applied to the prevention and treatment of diseases, and are known to be effective in inhibiting proliferation and decay activity against intestinal rot and pathogens. (Schrezenmeir J, De Vrese M: Am J Clin Nutr. 73 (2001), P 361S-4S) Probiotics inhibit the growth of harmful bacteria that produce ammonia, amines, etc. It has also been reported that the amount of nitrogen decreases to improve symptoms of liver disease. In addition, these useful bacteria have been reported to protect the liver from alcohol and improve its specific function. (Raibaud, P: The 3rd International Synposium on Lactic Acid Bacteria and Human Health. (1983), P116-126). Research has been reported of the possibility of actively promoting metabolism to rapidly decompose alcohol and to metabolize and detoxify acetaldehyde, which is harmful to the human body produced in this process. (Nosava. T. et al: Alcohol and Alcoholism. 35 (2000), P561-568)
이에, 본 발명자는 프로바이오틱스 유산균들 중에서 알코올에 대한 내성을 가지며, 알코올 분해효소를 가지고 있어 알코올을 분해할 수 있는 능력을 보유한 장내 서식용 프로바이오틱스를 선정하여 알코올 분해에 대한 기작과 혈중 알코올 농도의 감소효과를 동물실험을 통하여 확인한 결과, 락토바실러스 퍼멘텀(KCTC 10713BP)이 알코올 분해능이 매우 우수함을 발견하여 본 발명을 완성하기에 이르렀다. Accordingly, the present inventors select the intestinal habitat probiotics having alcohol resistance among probiotics lactic acid bacteria, having alcohol degrading enzymes, and having the ability to decompose alcohol, thereby reducing the mechanism of alcohol degradation and reducing the blood alcohol concentration. As a result of confirming through animal experiments, Lactobacillus permanent (KCTC 10713BP) was found to have a very good alcohol resolution to complete the present invention.
따라서, 본 발명의 목적은 알코올 분해능이 우수한 락토바실러스 퍼멘텀을 제공하는 것이다. 본 발명의 또 다른 목적은 상기 락토바실러스 퍼멘텀을 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제를 제공하는 것이다.Accordingly, it is an object of the present invention to provide Lactobacillus percentage which is excellent in alcohol resolution. Still another object of the present invention is to provide dairy products, health functional foods and food additives containing the Lactobacillus fermentum.
상기한 목적을 달성하기 위해서, 본 발명은 알코올에 대한 내성을 가지며, 알코올 분해효소를 가지고 있어 알코올을 분해할 수 있는 능력을 보유한 락토바실러스 퍼멘텀(KCTC 10713BP)을 포함하는 알코올 분해능이 있는 유산균을 제공한다.In order to achieve the above object, the present invention is an alcohol-degradable lactic acid bacteria, including Lactobacillus fermentum (KCTC 10713BP) that has the ability to decompose alcohol having a resistance to alcohol, alcohol degrading enzymes to provide.
이하, 본 발명을 더욱 구체적으로 설명하면 다음과 같다.Hereinafter, the present invention will be described in more detail.
락토바실러스 퍼멘텀(Lactobacillus fermentum)은 김치에 존재하는 유산균을 분리하여 우유를 주성분으로 하는 활성배지에서 37~42℃의 온도로 15~24시간 동안 배양하여 발효유에 적용할 수 있는 유산균으로 분리하여 얻어졌다.Lactobacillus fermentum is obtained by separating the lactic acid bacteria present in kimchi and incubating for 15 to 24 hours at 37-42 ℃ temperature in the active medium containing milk as a main component to separate the lactic acid bacteria that can be applied to fermented milk lost.
이것을 벌쥐 매뉴얼(Bergy's manual)의 락토바실러스 속 균주의 특성에 따라 현미경 검경, 그램염색, 커탈라제 생성여부 등을 검사하고, 동정 키트(Kit)인 API 50 CHL 배지(Medium)를 활용하여 탄수화물의 자화성을 측정한 결과, 그람양성, 통성혐기성, 무포자성, 커탈라제 음성인 락토바실러스 퍼멘텀의 새로운 균주임을 확인하였다. 이를 2004년 11월 2일자로 기탁하여, 수탁번호 KCTC 10713BP를 수여받았다.Microscopy, gram staining, and catalase production were examined according to the characteristics of Lactobacillus strains in the Bergy's manual, and carbohydrates were identified using API 50 CHL medium (Kit). As a result of measuring the magnetization, it was confirmed that it is a new strain of Lactobacillus pertumtum that is gram positive, anaerobic, no spore, and catalase negative. It was deposited on November 2, 2004 and was given accession number KCTC 10713BP.
본 발명에서 선발된 락토바실러스 퍼멘텀과 종래에 공지된 락토바실러스 균주 및 그 외의 임상균주들의 10% EtOH 내성, 내산성, 내담즙성, 알코올 분해효소 활성, 알데하이드 분해효소 활성을 평가한 결과를 하기 표 1에 나타내었다.The results of evaluating 10% EtOH resistance, acid resistance, bile resistance, alcoholase activity, and aldehyde degrading enzyme activity of Lactobacillus percentage and selected Lactobacillus strains and other clinical strains selected in the present invention are shown in the following table. 1 is shown.
상기 표 1에서 +++ 는 아주 좋음을, ++ 는 좋음을, + 는 약간 좋음을, 그리고 - 는 좋지 않음을 나타낸다.In Table 1, +++ is very good, ++ is good, + is slightly good, and-is not good.
상기 표 1에서 보는 바와 같이, 본 발명에서 선발된 락토바실러스 퍼멘텀은 종래의 공지된 균주 및 여러 임상균주에 비해서 10% EtOH 내성, 내산성, 내담즙성, 알코올 분해효소 활성 및 알데하이드 분해효소 활성에서 균형있게 모두 우수하였다.As shown in Table 1, the selected Lactobacillus permanentum in the present invention in 10% EtOH resistance, acid resistance, bile resistance, alcohol degrading enzyme activity and aldehyde degrading enzyme activity compared to conventional known strains and various clinical strains All were well balanced.
이하, 실시예에 의거하여 본 발명을 보다 상세히 설명하면 다음과 같다. 하기 실시예는 본 발명의 이해를 보다 용이하게 하기 위하여 제공되는 것이지만, 본 발명의 범위가 이들 실시예로 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples. The following examples are provided to facilitate the understanding of the present invention, but the scope of the present invention is not limited to these examples.
실시예 1: 에탄올 농도에 따른 내성 검사Example 1 Resistance Test According to Ethanol Concentration
에탄올 농도에 따른 내성 검사 방법에 대해서 간략히 설명하면, 먼저 사전 멸균한 MRS 액체배지에 멤브래인 필터(membrane filter)로 제균한 10% 에탄올을 첨가한 후, MRS 액체배지에서 활성화시킨 유산균을 소정량 첨가하여 37℃의 온도에서 24시간 동안 정치배양하였다. 그리고, 유산균의 균체량을 흡광도로 측정하였다.The resistance test method according to the ethanol concentration is briefly described. First, 10% ethanol sterilized with a membrane filter is added to a pre-sterilized MRS liquid medium, and then a predetermined amount of the lactic acid bacteria activated in the MRS liquid medium is added. Add and incubate for 24 hours at a temperature of 37 ℃. And the cell mass of lactic acid bacteria was measured by absorbance.
상기와 같은 방법으로 측정한 검사 결과를 하기 표 2에 나타내었다.The test results measured in the same manner as shown in Table 2 below.
실시예 2: 알코올 분해효소(ADH) 활성 및 알데하이드 분해효소(ALDH) 활성 검사Example 2: Alcohol Degrading Enzyme (ADH) Activity and Aldehyde Degrading Enzyme (ALDH) Activity Test
알코올 분해효소 활성 및 알데하이드 분해효소 활성 검사 방법은 먼저, MRS 액체배지에 배양하여 유산균 균체만을 회수하고, 10mM 소디움 포스페이트 버퍼(Sodium phosphate buffer)(pH 7.5)에 재현탁시킨 후, 얼음배스(Ice bath)에서 3분간 초음파 분쇄기로 균체를 파쇄하였다. 그리고, 상기 파쇄된 균체액을 4℃의 온도에서 10000~16000rpm의 조건으로 60~90분간 원심분리하여 유산균체의 세포질을 수확하였다.The alcohol degrading enzyme and aldehyde degrading enzyme activity test method was first cultured in MRS liquid medium to recover only the lactic acid bacteria cells, resuspended in 10 mM sodium phosphate buffer (pH 7.5), and then ice bath (Ice bath) The cells were crushed by using an ultrasonic grinder for 3 minutes. The pulverized cell solution was centrifuged for 60 to 90 minutes at a temperature of 4 ° C. at 10000 to 16000 rpm to harvest the cytoplasm of the lactic acid cells.
알코올 분해 효소의 측정은 알코올을 기질로 하여 NAD 환원정도를 측정하였으며, 알데하이드 분해효소의 측정은 아세트알데하이드를 기질로 하여 NAD 환원정도를 측정하였다.Alcohol degrading enzyme was measured for NAD reduction using alcohol as a substrate, and aldehyde degrading enzyme was measured for acetaldehyde as NAD reduction.
이와같이 측정한 결과를 하기 표 3에 나타내었다.Thus measured results are shown in Table 3 below.
실시예 3: SDS-PAGE를 통한 효소확인 검사Example 3: Enzyme Identification Test through SDS-PAGE
상기 실시예 2의 결과인 상기 표 3에서 나타난 높은 효소활성을 보유하고 있는 유산균으로 부터 알코올 분해효소와 알데하이드 분해효소가 생산되는가를 확인하기 위해 SDS-PAGE를 이용하여 램나이(Laemmli)법에 따라 15% 아크릴아미드(acrylamide)와 0.1% SDS를 함유하는 겔(gel)에서 수행하였다.According to the Laemmli method using SDS-PAGE to determine whether alcohol degrading enzyme and aldehyde degrading enzyme are produced from lactic acid bacteria having high enzymatic activity shown in Table 3 as a result of Example 2 It was performed on a gel containing 15% acrylamide and 0.1% SDS.
검사를 위한 시료는 상기 실시예 2에서와 동일한 방법으로 처리하여 세포질을 얻은 후 사용하였다.Samples for the test were used in the same manner as in Example 2 after obtaining the cytoplasm.
본 실시예에서 실시한 효소확인 검사 결과가 도 1에 도시되어 있다. 도 1에서 A는 마커, B는 표준 ALDH(Baker's yeast), C는 표준 ADH(Baker's yeast), D는 실험군으로서 10% 에탄올을 첨가한 락토바실러스 퍼멘텀 액체배지, E는 대조군으로서 락토바실러스 퍼멘텀 액체배지, F는 락토바실러스 액시도필러스, G는 락토바실러스 가세리이다.Enzyme confirmation test results carried out in this embodiment is shown in FIG. In Figure 1, A is a marker, B is a standard ALDH (Baker's yeast), C is a standard ADH (Baker's yeast), D is a Lactobacillus permanent liquid medium added with 10% ethanol as an experimental group, E is Lactobacillus permanent medium as a control Liquid medium, F is Lactobacillus axidophyllus, G is Lactobacillus gasteria.
도 1에 나타난 바와 같이, 락토바실러스 퍼멘텀의 ADH 분자량은 약 40kDa으로 표준 ADH와 유사한 크기이다. 10% 알코올을 첨가한 락토바실러스 퍼멘텀 액체배지의 경우(D) ADH 밴드가 10% 알코올을 첨가하지 않은 경우(E)보다 진한 것을 알 수 있다. 이는 알코올을 첨가할 경우, ADH의 발현이 증가하였음을 보여주는 것이다. 또한, 이전의 실험 결과에서 미비한 활성을 가졌던 락토바실러스 액시도필러스(F)의 경우에는 동일한 크기의 밴드가 약하게 나타났으며, 활성이 없는 락토바실러스 가세리(G)의 경우에는 전혀 밴드가 나타나지 않았다. As shown in FIG. 1, the Lactobacillus permanentum 's ADH molecular weight is about 40 kDa, similar in size to standard ADH. In the case of Lactobacillus permanent liquid medium added with 10% alcohol (D), it can be seen that the ADH band is darker than that without adding 10% alcohol (E). This shows that the expression of ADH increased when alcohol was added. In addition, in the case of Lactobacillus axidophilus (F), which had inadequate activity in previous experiments, bands of the same size were weak, and in the case of inactive Lactobacillus gaseri (G), no band appeared at all. Did.
ALDH의 경우도 10% 알코올을 첨가한 락토바실러스 퍼멘텀 액체배지의 경우(D)에 미비하지만 밴드가 나타남을 확인할 수 있었다.In case of ALDH, lactobacillus permanent liquid medium to which 10% alcohol was added was inadequate, but a band appeared.
실시예 4: 알코올 분해능 검사Example 4: Alcohol Resolution Test
본 실시예에서는 상기 실시예 2에서 높은 효소활성을 보유하고 있는 유산균에 의한 알코올 분해 정도를 확인하기 위하여, 가스 크로마토그래피(Gas chromatography)를 활용하여 배양 4시간 경과 후 10% 알코올을 액체배지에 첨가하고 2시간 간격으로 알코올의 분해정도를 측정하였다.In this example, in order to confirm the degree of alcohol degradation by the lactic acid bacteria having high enzymatic activity in Example 2, 10% alcohol was added to the liquid medium after 4 hours of cultivation using gas chromatography. Then, the decomposition degree of alcohol was measured at 2 hour intervals.
이때, 가스 크로마토그래피 분석방법은 공지방법(Kim, J.H. et al., J. Microbial. Biotechnol. 13 (2003), 919-925)을 이용하였으며, 대조군에는 유산균을 첨가하지 않았으며, 실험군에는 락토바실러스 퍼멘텀을 첨가하였다.At this time, the gas chromatography analysis method (Kim, JH et al., J. Microbial. Biotechnol. 13 (2003), 919-925) was used, the lactic acid bacteria were not added to the control group, Lactobacillus to the experimental group. Permanent was added.
하기 표 4에 배양시간에 따른 알코올 분해능을 검사한 결과를 나타내었다.Table 4 shows the results of testing the alcohol resolution according to the incubation time.
상기 표 4에 나타난 바와 같이, 시간이 지날수록 실험군의 알코올 함량은 감소하는 반면, 대조군의 알코올 함량은 일정한 것을 알 수 있다.As shown in Table 4, as time passes, the alcohol content of the experimental group decreases, while the alcohol content of the control group is found to be constant.
실시예 5: 간세포 배양을 통한 간기능 효과 검사Example 5 Examination of Hepatic Function Effect by Hepatocyte Culture
본 실시예에서는 본 발명의 알코올 분해능이 우수한 락토바실러스 퍼멘텀의 간세포 배양을 통한 간기능 효과를 확인하기 위해, 8주령의 스프래그-돌리(Sprague-Dawley) 쥐로부터 세그렌(Seglen)의 투스텝 인 시츄 콜라게나제 펄퓨젼 테크닉(two-step in situ collagenase perfusion technique) 방법으로 간세포(Hepatocytes)를 분리하여 DMEM(Dulbecco's Modified Eagle Medium) 배지에 대조군, 10% 알코올 첨가군, 10% 알코올과 유산균 세포질 첨가군, 20% 알코올과 유산균 세포질 첨가군으로 분류하여 7일간 배양한 후, 현미경으로 간세포의 상태를 관찰하여 도 2에 나타내었다.In this example, in order to confirm the effect of liver function through the hepatocyte culture of Lactobacillus fermentum excellent in alcohol resolution of the present invention, two-step-in of Seglen from 8-week-old Sprague-Dawley rats Hepatocytes were isolated by two-step in situ collagenase perfusion technique and added to DMEM (Dulbecco's Modified Eagle Medium) medium with 10% alcohol, 10% alcohol and lactic acid bacteria cytoplasm. After grouping the cells into 20% alcohol and lactic acid bacteria cytoplasmic addition group and incubating for 7 days, the state of the hepatocytes was observed under a microscope and shown in FIG. 2.
도 2에서 A1은 아무것도 첨가하지 않은 대조군의 실험 전 상태, A2는 상기 A1의 실험 후 상태, B1은 10% 알코올을 첨가한 배지의 실험 전 상태, B2는 상기 B1의 실험 후 상태, C1은 10% 알코올과 유산균 세포질을 첨가한 배지의 실험 전 상태, C2는 상기 C1의 실험 후 상태, D1는 20% 알코올과 유산균 세포질을 첨가한 배지의 실험 전 상태, D2는 상기 D1의 실험 후 상태이다.In Figure 2, A1 is the pre-experimental state of the control group to which nothing is added, A2 is the post-experimental state of A1, B1 is the pre-experimental state of the medium to which 10% alcohol is added, B2 is the post-experimental state of B1, C1 is 10 The pre-experimental state of the medium containing% alcohol and lactic acid bacteria cytoplasm, C2 is the post-experimental state of the C1, D1 is the pre-experimental state of the medium to which the 20% alcohol and lactic acid cytoplasm was added, and the D2 is the post-experimental state of the D1.
도 2에 나타난 바와 같이, 알코올과 락토바실러스 퍼멘텀의 세포질이 함유된 간세포(C2)가 알코올 만을 첨가한 경우(B2)보다 살아있는 세포가 많음이 관찰되었으며, 알코올 만을 첨가한 경우(B2)에는 대부분의 간세포가 플레이트에서 떨어져 나온 것을 볼 수 있었다. 그러나, 락토바실러스 퍼멘텀의 세포질을 첨가한 경우(C2, D2)에는 간세포가 유지되어짐을 알 수 있었으며, 락토바실러스 퍼멘텀 세포질의 농도를 달리한 경우(C2, D2)에는 큰 차이를 나타내지 않았다.As shown in Figure 2, it was observed that hepatocytes (C2) containing cytoplasm of alcohol and Lactobacillus fermentum had more living cells than alcohol (B2), and mostly alcohol (B2). Hepatocytes were seen to come off the plate. However, it was found that the hepatocytes were maintained when the cytoplasm of Lactobacillus fermentum was added (C2, D2), and there was no significant difference when the concentrations of the Lactobacillus fermentum cytoplasm were changed (C2, D2).
상기 실험을 통해서 락토바실러스 퍼멘텀이 간세포의 손상을 줄이고 세포활 성을 유지시켜줌을 확인할 수 있었다.Through the above experiments, it was confirmed that Lactobacillus permanentment reduces the damage of hepatocytes and maintains cell activity.
실시예 6: 쥐를 이용한 혈중 알코올 감소 효과 검사Example 6 Blood Alcohol Reduction Effect Test in Mice
본 실시예에서는 쥐를 이용한 혈중 알코올 농도 감소 효과를 측정하기 위해, 스프래그-돌리(Sprague-Dawley) 쥐에 락토바실러스 퍼멘텀 유산균 배양액과 22%의 알코올을 같은 양으로 경구투여 하고 2시간 경과 후, 혈액을 채취하여 혈중 알코올 농도, GOT(Glutamic-oxaloacetic transaminase) 및 GPT(Glutamic pyruvic transaminase)를 측정하였다.In this example, 2 hours after oral administration of Lactobacillus fermentum lactobacillus culture medium and 22% alcohol to Sprague-Dawley rats in order to measure the effect of reducing blood alcohol concentration using rats Blood samples were collected and blood alcohol levels, GOT (glutamic-oxaloacetic transaminase) and GPT (glutamic pyruvic transaminase) were measured.
하기 표 5에 본 실시예 6의 검사결과를 나타내었으며, 여기에서 대조군은 22%의 알코올을 3㎖ 투여하였으며, 실험군은 22%의 알코올 3㎖와 함께 락토바실러스 퍼멘텀 유산균을 투여하였다.Table 5 shows the test results of Example 6, where the control group was administered with 3 ml of 22% alcohol, and the experimental group was administered Lactobacillus fermentum lactic acid bacteria with 3 ml of 22% alcohol.
상기 표 5에 나타난 바와 같이, 락토바실러스 퍼멘텀 유산균을 투여한 실험군은 대조군에 비해 혈중 알코올 농도, GOT, GPT 모두 현저히 낮은 것을 발견하였다.As shown in Table 5, the experimental group administered Lactobacillus Permanent Lactobacillus was found to be significantly lower in blood alcohol concentration, GOT, GPT than the control group.
한편, 본 발명에 따른 락토바실러스 퍼멘텀 유산균를 함유하는 유제품, 건강 기능성 식품 및 식품 첨가제의 제조 및 그의 함량은 당업계에 공지된 통상적인 방 법으로부터 용이하게 파악될 수 있으며, 식품내에서의 유산균 생존성을 유지하기 위한 다른 물질 등도 함유할 수 있다.On the other hand, the production of dairy products, health functional foods and food additives containing Lactobacillus permentum lactic acid bacteria according to the present invention and the content thereof can be easily determined from conventional methods known in the art, lactic acid bacteria survival in food It may also contain other substances for maintaining the properties.
이상에서 살펴본 바와 같이, 본 발명에서 선발한 락토바실러스 유산균인 락토바실러스 퍼멘텀(기탁번호: KCTC 10713BP)은 내산성과 내담즙성 및 우유 배양성 등이 뛰어나면서도 특히 알코올 분해능이 탁월하기 때문에, 알코올성 간질환을 예방하는의약품, 유제품, 건강 기능성 식품 및 식품 첨가물에 포함시킬 경우 숙취해소 효과와 간 해독작용 효과를 얻을 수 있다.As described above, the Lactobacillus lactic acid bacterium selected from the present invention (Lactobacillus permentum (Accession Number: KCTC 10713BP)) is excellent in alcohol resistance, especially because of excellent acid resistance and bile resistance and milk culture, alcoholic liver When included in medicines, dairy products, dietary supplements, and food additives to prevent disease, it is possible to achieve hangover and liver detoxification.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040104153A KR100769299B1 (en) | 2004-12-10 | 2004-12-10 | Lactobacillus fermentum and dairy products and health-promoting food containing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020040104153A KR100769299B1 (en) | 2004-12-10 | 2004-12-10 | Lactobacillus fermentum and dairy products and health-promoting food containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060065753A KR20060065753A (en) | 2006-06-14 |
KR100769299B1 true KR100769299B1 (en) | 2007-10-24 |
Family
ID=37160789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020040104153A KR100769299B1 (en) | 2004-12-10 | 2004-12-10 | Lactobacillus fermentum and dairy products and health-promoting food containing the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100769299B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI480045B (en) * | 2012-09-17 | 2015-04-11 | Univ Hungkuang | Prevention and/or alleviation of alcoholic liver disease with a mixture of four lactic acid bacteria strains |
KR102078324B1 (en) | 2019-10-08 | 2020-02-18 | 주식회사 웰빙엘에스 | Composition for removing hangover and disorders of intestinal comprising grain-origin lactic acid bacteria |
KR20230101595A (en) | 2021-12-29 | 2023-07-06 | (주)비타바이오 | Novel Leuconostoc lactis VITA-PK5, KCTC18965P and composition for relieving hangover comprising thereof |
KR20240055956A (en) | 2022-10-20 | 2024-04-30 | 유기종 | Novel Pediococcus pentosaceus VITA-PK1, KCTC 19035P and composition for relieving hangover comprising thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101853603B1 (en) * | 2017-05-18 | 2018-05-02 | 주식회사 쎌바이오텍 | Composition containing of probiotics for using alcohol or acetaldehyde dehydrogenase activity |
KR101880651B1 (en) | 2017-12-29 | 2018-07-20 | 주식회사 메디톡스 | Microorganism capable of degrading ethanol and acetaldehyde, composition and kit comprising the same |
CN116268422A (en) * | 2023-03-29 | 2023-06-23 | 扬州大学 | Application of lactobacillus fermentum grx08 in preparation of food and functional food and medicine with effects of relieving alcoholic liver injury and related symptoms thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060059588A (en) * | 2004-11-29 | 2006-06-02 | 주식회사한국야쿠르트 | Lactic acid bacteria degrading alcohol and acetaldehyde |
-
2004
- 2004-12-10 KR KR1020040104153A patent/KR100769299B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060059588A (en) * | 2004-11-29 | 2006-06-02 | 주식회사한국야쿠르트 | Lactic acid bacteria degrading alcohol and acetaldehyde |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI480045B (en) * | 2012-09-17 | 2015-04-11 | Univ Hungkuang | Prevention and/or alleviation of alcoholic liver disease with a mixture of four lactic acid bacteria strains |
KR102078324B1 (en) | 2019-10-08 | 2020-02-18 | 주식회사 웰빙엘에스 | Composition for removing hangover and disorders of intestinal comprising grain-origin lactic acid bacteria |
KR20230101595A (en) | 2021-12-29 | 2023-07-06 | (주)비타바이오 | Novel Leuconostoc lactis VITA-PK5, KCTC18965P and composition for relieving hangover comprising thereof |
KR20240055956A (en) | 2022-10-20 | 2024-04-30 | 유기종 | Novel Pediococcus pentosaceus VITA-PK1, KCTC 19035P and composition for relieving hangover comprising thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20060065753A (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110835616B (en) | Active substance of lactobacillus paracasei GKS6, composition containing same and application of active substance in promoting longevity | |
KR101371648B1 (en) | Lactobacillus brevis with high alcohol dehydrogenase activity and dairy products, health functional food and food additives comprising the same | |
KR101618391B1 (en) | Lactic acid bacterium having high oxalic acid decomposition ability | |
KR101333758B1 (en) | Lactobacillus plantarum with high acetaldehyde dehydrogenase activity and dairy products, health functional food and food additives comprising the same | |
Schneedorf | Kefir D’Aqua and its probiotic properties | |
CN110833565B (en) | Active substance of lactobacillus plantarum GKM3, composition containing same and application of active substance in promoting longevity | |
CN111925961A (en) | Lactobacillus plantarum Lp2 and application thereof | |
CN115322932B (en) | Lactobacillus plantarum with anti-alcohol and sobering-up capabilities and application thereof | |
CN105420150A (en) | Lactobacillus acidophilus and application thereof | |
CN110835615B (en) | Active substance of bifidobacterium lactis GKK2, composition containing same and application of active substance and composition in promoting longevity | |
KR100769299B1 (en) | Lactobacillus fermentum and dairy products and health-promoting food containing the same | |
US20200330530A1 (en) | Hepatoprotection food composition and pharmaceutical composition with strains of lactic acid bacteria | |
KR20160063024A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
KR102536627B1 (en) | Composition for preventing or improving alcoholic liver injury comprising fermented kiwi | |
Zhou et al. | Probiotic properties of Lactobacillus paraplantarum LS-5 and its effect on antioxidant activity of fermented sauerkraut | |
CN116814501A (en) | Bifidobacterium longum subspecies capable of relieving obesity and application thereof | |
KR101010913B1 (en) | Lactobacillus plantarum having antihypertensive activity and fermented products containing it | |
KR100910657B1 (en) | Novel Lactrobacillus buchneri and use thereof | |
KR20190075039A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
Sasmita et al. | Potential use of fermented dangke cheese to improve glycemic control in rats fed with a high-fat glucose diet and propylthiouracil | |
KR101672098B1 (en) | Composition for removing hangover comprising fermented rice rinse water | |
KR20170045190A (en) | Lactobacillus plantarum KCC-24 and composition comprising the same | |
KR102055053B1 (en) | Starter containing of lactic acid bacteria with superior effect for alcohol degradation activity and cheese containing alcohol metabolism using the same | |
Hutahaean et al. | Characterisation of lactic acid bacteria from Dengke Naniura of common carp (Cyprinus carpio) with α-glucosidase inhibitory activity | |
CN116656526B (en) | Lactobacillus plantarum JF4 and application thereof in preparation of blood sugar and cholesterol reducing foods and medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121016 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131011 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141002 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151006 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161005 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171012 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181017 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20191001 Year of fee payment: 13 |